MSFP
JAZZ icon

Mark Sheptoff Financial Planning’s Jazz Pharmaceuticals JAZZ Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6
Closed -$1K – 467
2021
Q3 		$1K Sell
6
-208
-97% -$31.4K ﹤0.01% 382
2021
Q2 		$38K Buy
+214
New +$37.1K 0.02% 211

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mark Sheptoff Financial Planning's JAZZ Position: Q4 2021 in Review

Mark Sheptoff Financial Planning sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2021, closing a stake of 6 shares — an estimated $1K sold.

Mark Sheptoff Financial Planning first reported a position in JAZZ in Q2 2021 and held it in 2 quarters. The position peaked at $38K in Q2 2021. 454 funds tracked by Wall St. Rank hold JAZZ as of Q4 2021.

  • Mark Sheptoff Financial Planning reported no remaining Jazz Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Mark Sheptoff Financial Planning sold 6 Jazz Pharmaceuticals shares in Q4 2021, an estimated $1K.
  • Mark Sheptoff Financial Planning first reported a position in Jazz Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Mark Sheptoff Financial Planning's Jazz Pharmaceuticals position peaked at $38K in Q2 2021.
  • 454 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2021.

Based on Mark Sheptoff Financial Planning's 13F filing for Q4 2021, filed 11 Feb 2022.